A unique systems pharmacology platform powered by AI to accelerate drug discovery. Uses disruptive AI technology to accelerate the entire drug discovery process by identifying promising candidates, de-risking the opportunities through preclinical validations, and progressing drug candidates to the clinic through industry and investor partnerships
Dexamethasone identified by AI VIVO as high potential for treatment of COVID-19 ten weeks ago
Dexamethasone identified by AI VIVO as high potential for treatment of COVID-19 ten weeks ago
Investors 2
| Date | Name | Website |
| - | o2h ventur... | o2hventure... |
| - | Martlet | martletcap... |
Mentions in press and media 3
| Date | Title | Description |
| 22.09.2021 | Introducing: the 32 companies joining the Applied AI programme in 2021 | We are excited to announce the 32 AI companies selected for the third iteration of Tech Nation’s Applied AI growth programme. Companies accepted into the newest cohort are also applying AI to create real-world impact in the fields of data ... |
| 07.05.2020 | AI VIVO seeks collaboration partners to progress top-ranked COVID-19 therapeutic candidates | AI VIVO seeks collaboration partners to progress top-ranked COVID-19 therapeutic candidates 07-05-2020 AI VIVO, the Cambridge based company combining systems pharmacology and artificial intelligence (AI) to accelerate drug discovery, has an... |
| 16.04.2020 | COVID-19 breakthrough as Cambridge company identifies top ranked drugs for treatment | COVID-19 breakthrough as Cambridge company identifies top ranked drugs for treatment 16-04-2020 A revolutionary systems pharmacology platform powered by artificial intelligence has identified the top candidate drugs that are highly likely t... |